FIELD: medicine.
SUBSTANCE: present group of inventions relates to medicine, namely to oncology, and concerns the classification of patients suffering from solid cancer. To do this, at least two biological markers characterizing the patient's immune response to his existing solid cancer are quantified, these values are compared with the distribution of the values obtained for these markers from the control group of patients with the same cancer, the percentiles of the distribution of the obtained values are determined and percentile mean values are compared with a preset control percentile mean that are correlated with survival time or patient response to treatment.
EFFECT: said invention enables accurate in vitro prediction of survival time as well as patient responsiveness to anticancer treatment.
19 cl, 2 tbl, 1 ex, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR MULTI ANALYSES OF RARE CELLS EXTRACTED OR ISOLATED FROM BIOLOGICAL SAMPLES BY FILTERING | 2013 |
|
RU2641595C2 |
| METHOD FOR CONDUCTING MULTI-ASSAYS OF RARE CELLS EXTRACTED OR ISOLATED FROM BIOLOGICAL SAMPLES BY FILTRATION | 2013 |
|
RU2765808C2 |
| RECOMBINANT VACCINE OF FELINE LEUKEMIA VIRUS CONTAINING OPTIMISED GENE OF FELINE LEUKEMIA VIRAL ENVELOPE | 2012 |
|
RU2591817C2 |
| DIAGNOSING AND TREATING BREAST CANCER | 2011 |
|
RU2550925C2 |
| IMMUNE CELLS DEFECTIVE BY Suv39h1 | 2018 |
|
RU2784531C2 |
| PHOSPHODIESTERASE 9A AS MARKER OF MALIGNANT TUMOR OF PROSTATE GLAND | 2010 |
|
RU2592668C2 |
| METHOD OF DIAGNOSING NEOPLASM-II | 2008 |
|
RU2565540C2 |
| IDENTIFICATION OF TUMOUR-ASSOCIATED ANTIGENS FOR DIAGNOSTICS AND THERAPY | 2013 |
|
RU2644686C2 |
| REPRESENTATIVE DIAGNOSIS | 2016 |
|
RU2743169C2 |
| METHODS AND COMPOSITIONS FOR TREATING TUMORS | 2017 |
|
RU2741786C2 |
